Alcohol-Associated Hepatitis

Improvements in intrahepatic and circulatory inflammation markers were observed after fecal microbiota transplantation in patients with severe alcohol associated hepatitis, according to a presenter at The Liver Meeting Digital Experience.

A 6-month Lactobacillus rhamnosus GG treatment for moderate alcohol-associated hepatitis correlated with a decrease in heavy drinking levels to the social drinking or abstinence levels, according to a presentation.

There was an 81% increase in alcohol-associated hepatitis admissions within the first year of the COVID-19 pandemic and resulted in a significant increase in liver transplantation, according to a presentation.

In this exclusive video, Steven Flamm, MD, chief of the liver program at the Northwestern Feinberg School of Medicine, discusses a potential treatment for alcoholic hepatitis that is currently in development.

People who carry a certain genetic variant are at lower risk for developing severe alcoholic hepatitis, according to research presented at The Digital International Liver Congress.

The carriage of virulence factors in the commensal gut microbiota was associated with mortality in patients with alcoholic hepatitis, according to research presented at The Digital International Liver Congress.

Nonalcoholic steatohepatitis is a severe form of fatty liver disease that affects 3% to 5% of the population in the United States and currently no approved drugs are available for treatment, according to a press release from Durect Corporation.

Hepatitis C virus infection remains a strong driver of hepatocellular carcinoma with a high rate of progression to cirrhosis over an extended follow-up period, according to a study in International Journal of Molecular Sciences.

MAUI, Hawaii — To better manage alcohol-associated hepatitis, standards for the liver transplantation process should be altered as liver transplantation gains support as a therapeutic option for this disease, according to an expert at GUILD Conference 2020.

BOSTON — In this exclusive video from The Liver Meeting 2019, Tarek Hassanein, MD, FAASLD, professor of medicine at UC San Diego Health and medical director of Southern California GI and Liver Centers, discusses results of a phase 2a study, which demonstrated that DUR-928 was well-tolerated and effective in patients with acute alcoholic hepatitis.